X
Gilead’s Kite gains some height after second CAR-T approval in US
https://pharmaphorum.com/news/gileads-kite-gains-some-height-after-second-car-t-approval-in-us/
Kite Pharma
Ex-Kite chiefs’ biotech to research ‘off-the-shelf’ CAR-Ts with Cellectis
Belldegrun and Chang’s Allogene to take over from Pfizer in R&D deal
Gilead completes $11.9bn Kite acquisition
Gilead’s focus shifts from hepatitis C to CAR-T
Novartis’ CAR-T drug needs new payment model, says Express Scripts
Cost of Novartis’ revolutionary therapy is obstacle, says CMO.
Gilead swoops to buy Kite for $12billion
Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
Real world data essential for CAR-T therapy success
Innovators will need to quantify value to bring costly drugs to market.
Scottish firm gets EU funding for ‘off the shelf’ cancer cell therapy
First patients could be treated in 2019.